254 related articles for article (PubMed ID: 32215055)
1. PARP inhibitor combinations in prostate cancer.
Pezaro C
Ther Adv Med Oncol; 2020; 12():1758835919897537. PubMed ID: 32215055
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
3. Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Boussios S; Karihtala P; Moschetta M; Karathanasi A; Sadauskaite A; Rassy E; Pavlidis N
Diagnostics (Basel); 2019 Aug; 9(3):. PubMed ID: 31374917
[TBL] [Abstract][Full Text] [Related]
4. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
Unlu S; Kim JW
Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
6. Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.
Zhang Y; Liang L; Li Z; Huang Y; Jiang M; Zou B; Xu Y
Front Oncol; 2023; 13():1295579. PubMed ID: 38111536
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors and more.
Bose CK; Basu N
J Turk Ger Gynecol Assoc; 2015; 16(2):107-10. PubMed ID: 26097394
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Nambiar DK; Mishra D; Singh RP
Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
Yin L; Liu Y; Peng Y; Peng Y; Yu X; Gao Y; Yuan B; Zhu Q; Cao T; He L; Gong Z; Sun L; Fan X; Li X
J Exp Clin Cancer Res; 2018 Jul; 37(1):153. PubMed ID: 30012171
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer and PARP inhibitors: progress and challenges.
Teyssonneau D; Margot H; Cabart M; Anonnay M; Sargos P; Vuong NS; Soubeyran I; Sevenet N; Roubaud G
J Hematol Oncol; 2021 Mar; 14(1):51. PubMed ID: 33781305
[TBL] [Abstract][Full Text] [Related]
12. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
Inderjeeth AJ; Topp M; Sanij E; Castro E; Sandhu S
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497408
[TBL] [Abstract][Full Text] [Related]
13. Evolving DNA repair synthetic lethality targets in cancer.
Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibition in prostate cancer.
Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
[TBL] [Abstract][Full Text] [Related]
16. Use of PARP inhibitors in prostate cancer: from specific to broader application.
Zhang Z; Diao L; Zhang C; Wang F; Guan X; Yao X
Front Endocrinol (Lausanne); 2023; 14():1164067. PubMed ID: 37152924
[TBL] [Abstract][Full Text] [Related]
17. An Update on Poly(ADP-ribose) Polymerase I-A Brief Review.
Negi P; Lakshmanan K; Patel PK; Rajagopal K; Byran G
Mini Rev Med Chem; 2023; 23(18):1762-1771. PubMed ID: 36824002
[TBL] [Abstract][Full Text] [Related]
18. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
19. XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.
Maeda J; Haskins JS; Kato TA
Mutat Res; 2023; 826():111815. PubMed ID: 36812659
[TBL] [Abstract][Full Text] [Related]
20. New treatment option for ovarian cancer: PARP inhibitors.
Meehan RS; Chen AP
Gynecol Oncol Res Pract; 2016; 3():3. PubMed ID: 27231574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
